Skip to main content

Anifrolumab Reduces Lupus Flares

May 17, 2021 7:29 pm

Anifrolumab has been studied in two large phase 3 trials in systemic lupus erythematosus (SLE) patients; pooled data from both the TULIP-1 and TULIP-2 trials were used to show that anifrolumab reduces flares in patients with moderate to severe SLE. 

Anifrolumab is a human monoclonal antibody to type I interferon receptor subunit and is being developed to treat active SLE patients.

Patiens in TULIP-1 and TULIP-2 trials were studies for 52 weeks and either received placebo or intravenous anifrolumab 300 mg every 4 weeks. Flares were defined as ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B worsening compared to the prior visit. For those on glucocorticoid ≥10 mg/day a steroid taper was attempted between weeks 8-40.

When compared those treated with placebo, anifrolumab (n = 360) treated patient had 25% lower lower flare rates (rate ratio 0.75), prolonged time to first flare (hazard ratio 0.70) and fewer patients with ≥1 flare.

SLE patients who achieved sustained glucocorticoid reductions, more remained flare free with anifrolumab (40% vs 17.3% w/ PBO). 

Analysis of pooled TULIP-1 and TULIP-2 data shows anifrolumab reduces flares while permitting glucocorticoid taper in SLE patients.

The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.